Concepedia

J. Llovet

JL

Statistics

Publications

2

Citations

220

H-Index

2

Active since

2022

Affiliations

Kindai University(Current)

Merck & Co., Inc., Rahway, NJ, USA (United States)

Icahn School of Medicine at Mount Sinai

Fudan University

Zhongshan Hospital

J. Llovet is an author at Kindai University specializing in hepatology, cancer therapeutics, and medicine.

Top concepts

Publications per year

2022–2024

2

Publications

2

LBA34 Primary results from the phase III LEAP-002 study: Lenvatinib plus pembrolizumab versus lenvatinib as first-line (1L) therapy for advanced hepatocellular carcinoma (aHCC)

R.S. Finn, Masatoshi Kudo, Philippe Merle et al. · Annals of Oncology · 2022 · 192 citations

, , +9

LBA3 Transarterial chemoembolization (TACE) with or without lenvatinib (len) + pembrolizumab (pembro) for intermediate-stage hepatocellular carcinoma (HCC): Phase III LEAP-012 study

J. Llovet, R.S. Finn, Z. Ren et al. · Annals of Oncology · 2024 · 28 citations · Full text

, , +7

1–2 of 2